With a pharma market registering 4.2% growth, 38 million people, and a strategic location in the center of Europe, Poland possesses solid foundations for success in the healthcare and life sciences sector. The situation is improving for both generic medicine companies and innovators, and the Polish state – which has traditionally favored price-effective generic treatments – is beginning to leverage pharmaco-economic models more widely in order to create enhanced market access conditions for latest generation therapies.
To capitalize on the country’s well-educated and reasonably inexpensive human resource base, multinational companies are now flocking to Poland to establish manufacturing sites, global shared service centers and clinical trials facilities for the region and beyond.
Designed for pharmaceutical executives, this report examines each factor at play in Poland’s rapidly evolving healthcare and life sciences landscape. It addresses the fledgling, but highly prospective biosimilars niche, parallel trade, and therapeutic areas such as cardiology and women’s health; and features exclusive insights from some of the major pharma players and interviews with the most influential captains of industry.